BeiGene (688235.SH): European Commission approves Baizean for first-line and second-line treatment of three non-small cell lung cancer indications

Gelonghui, April 23 | BeiGene (688235.SH) announced recently that the European Commission has granted marketing license to Baizean (tirelizumab injection) and approved it for first-line and second-line treatment of three non-small cell lung cancer (NSCLC) indications: combination paclitaxel and carboplatin or injectable paclitaxel (albumin conjugated type) and carboplatin for use in first-line treatment of adult patients with platinum-containing radiotherapy; combined with chemotherapeutics containing platinum Used for PD-L1 expression ≥ 50% and no epidermis growth factor receptor (EGFR)

Gelonghui Finance18:24

The European Commission Approves BeiGene's Tislelizumab For Non-Small Cell Lung Cancer Across Three Indications, Including First-And-Second-Line Use

The European Commission Approves BeiGene's Tislelizumab For Non-Small Cell Lung Cancer Across Three Indications, Including First-And-Second-Line Use

Benzinga18:08

Pharmaceutical stocks continued to rise in the afternoon. Osecon moved up the market. BeiGene Shenzhou and Hengrui Pharmaceuticals both rose more than 4%, and the weights of the pharmaceutical industry such as Kangde, Aier Ophthalmology, and Mindray Healt

Pharmaceutical stocks continued to rise in the afternoon. Osecon moved up the market. BeiGene Shenzhou and Hengrui Pharmaceuticals both rose more than 4%, and the weights of the pharmaceutical industry such as Kangde, Aier Ophthalmology, and Mindray Healthcare collectively strengthened.

Zhitong Finance13:51

BeiGene (06160.HK) will hold a board audit committee meeting on May 8 to approve the first quarter results

Glonghui, April 22, 丨 BeiGene (06160.HK) announced that the audit committee meeting of the company's board of directors will be held on May 8, 2024 to review and approve the financial results and releases of the company and its subsidiaries for the three months ended March 31, 2024 in accordance with US GAAP and applicable rules of the US Securities and Exchange Commission.

Gelonghui FinanceApr 22 18:18

百濟神州：審計委員會會議日期

Futu NewsApr 22 18:16 · Announcements

BeiGene to Award Shares Worth $15 Million to 11 Directors

BeiGene (HKG:6160, SHA:688235) will grant restricted share units (RSUs) and performance share units (PSUs) to 11 directors under the firm's 2016 Share Option and Incentive Plan, according to a Tuesday

MT NewswiresApr 17 20:29